Serum from 52 NXP2+ by LB was available for testing by IP: anti-NXP2 antibodies were confirmed in 31 sera (60%), with the following diagnosis: DM 27 (87%), PM 3 (9.6%) and IBM 1 case (3.2%). The gene discussed is MORC3; the disease is inclusion body myositis.